The Digital Medicine Society (DiMe), in partnership with Anthem, Biogen, Eli Lilly, Evidation, Janssen, Merck, Pfizer and Savvy Co-op, announced the public launch of the 3Ps of Digital Endpoint Value (3Ps), a toolkit of resources created to facilitate the inclusion of digital endpoints as evidence for payers in reimbursement decisions for new drugs.

Eli Lilly and Company announced updated data from the Phase 1/2 LIBRETTO-001 trial of Retevmo (selpercatinib 40 mg & 80 mg capsules) in patients with RET fusion-positive non-small cell lung cancer (NSCLC).

The high cost of insulin to treat diabetes would be drastically reduced under legislation the U.S. House of Representatives passed on March 31, in a rare example of drug price reform gaining traction in Congress.

The U.S. Food and Drug Administration rejected Eli Lilly’s Biologics License Application, issuing a Complete Response Letter for the company’s PD-1 checkpoint inhibitor sintilimab.

More and more pharmaceutical companies are joining in the effort to put economic pressure on Russia by suspending some or all operations within that country following the invasion of Ukraine. 

U.S. drugmaker Eli Lilly said on March 15 the company would continue to supply drugs for urgent medical conditions such as cancer and diabetes to Russia, but will suspend all investments and no longer start new clinical studies in the country.

Scientists pinpointed 16 new genetic variants in people who developed severe COVID-19 in a large study published on March 7 that could help researchers develop treatments for very sick patients.

The U.S. health regulator approved Eli Lilly and partner Boehringer Ingelheim’s drug, Jardiance, for expanded use in reducing the risk of death and hospitalization for all patients with heart failure.

The World Health Organization indicated WHO is tracking four Omicron subvariants: BA.1, BA.1.1, BA.2 and BA.3. BA.2 has a growth advantage over BA.1, the variant responsible for the recent Omicron surge.

Lilly and Roche expressed their criticism of the draft guidance from the U.S. Centers for Medicare & Medicaid Services (CMS) for Biogen’s Alzheimer’s drug Aduhelm (aducanumab).